Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 299

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Delanoy, Nicolas, Michot, Jean-Marie, Comont, Thibault, Kramkimel, Nora, Lazarovici, Julien, Dupont, Romain, Champiat, Stéphane, Chahine, Claude, Robert, Caroline, Herbaux, Charles, Besse, Benjamin, Guillemin, Aude, Mateus, Christine, Pautier, Patricia, Saïag, Philippe, Madonna, Emanuela, Maerevoet, Marie, Bout, Jean-Christophe, Leduc, Charlotte, Biscay, Pascal, Quere, Gilles, Nardin, Charlée, Ebbo, Mikael, Albigès, Laurence, Marret, Grégoire, Levrat, Virginie, Dujon, Cécile, Vargaftig, Jacques, Laghouati, Salim, Croisille, Laure, Voisin, Anne-Laure, Godeau, Bertrand, Massard, Christophe, Ribrag, Vincent, Marabelle, Aurélien, Michel, Marc, Lambotte, Olivier · 2019 · The Lancet Haematology

Abstract

BACKGROUND Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). These adverse events can involve all organs, including the haemopoietic system. Thus far, haematological irAEs (haem-irAEs) have not been extensively characterised. This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1. METHODS In this descriptive observational study, we included consecutive patients aged at least 18 years with grade 2 or worse haem-irAEs induced by anti-PD-1 or anti-PD-L1 immunotherapy registered in three French pharmacovigilance databases: the Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC; a prospective registry of patients treated with anti-PD-1 or anti-PD-L1 at a single centre), the ImmunoTOX committee of Gustave Roussy (a national referral database of suspected irAEs in patients treated with immunotherapy), and the registry of the Centre de Référence des Cytopénies Auto-Immunes de l'Adulte (CeReCAI; a national database of autoimmune cytopenias). Cases were reviewed by a central committee; adverse events had to be classed as certainly or probably related to anti-PD-1 or anti-PD-L1 therapy, and their severity was assessed according to the Common Terminology Criteria for Adverse Events (version 4.03). The primary endpoint was clinical description of haem-irAEs, as reported in all databases, and their frequency, as reported in the prospective REISAMIC registry. FINDINGS We screened 948 patients registered in the three databases from June 27, 2014, to June 29, 2018 (745 from REISAMIC, 190 from the ImmunoTOX committee, and 13 from CeReCAI). 35 patients (21 men and 14 women) with haem-irAEs related to anti-PD-1 or anti-PD-L1 were included in the study. Of 745 patients in the REISAMIC registry treated with anti-PD-1 or anti-PD-L1, four had haem-irAEs, giving a frequency of 0·5%. Median age in the 35 patients was 65 years (IQR 51-75), and the most common tumour types were melanoma (15 [43%] patients), non-small-cell lung cancer (12 [34%] patients), and lymphoma (four [11%] patients). 20 (57%) patients received nivolumab, 14 (40%) received pembrolizumab, and one (3%) received atezolizumab. Among the 35 patients, neutropenia, autoimmune haemolytic anaemia, and immune thrombocytopenia were the most common types of haem-irAE (each in nine patients [26%]), followed by pancytopenia or aplastic anaemia (five patients [14%]), bicytopenia (one patients with thrombocytopenia plus anaemia and one patient with neutropenia plus anaemia [6%]), and pure red cell aplasia (one patient [3%]). The maximum grade of severity was grade 2 in three (9%) patients, grade 3 in five (14%) patients, and grade 4 in 25 (71%) patients; two (6%) patients died from febrile neutropenia during haem-irAE related to anti-PD-1. Haem-irAEs resolved in 21 (60%) of the 35 patients. INTERPRETATION Haem-irAEs induced by PD-1 or PD-L1 inhibitors are rare but potentially life-threatening events. The most common clinical presentations are neutropenia, autoimmune haemolytic anaemia, immune thrombocytopenia, and aplastic anaemia. Investigations into earlier detection and better management are warranted. FUNDING Gustave Roussy and Gustave Roussy Immunotherapy Program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(18)30175-3

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 299

Metadata

Authors
Delanoy, N., Michot, J.-M., Comont, T., Kramkimel, N., Lazarovici, J., Dupont, R., Champiat, S., Chahine, C., Robert, C., Herbaux, C., Besse, B., Guillemin, A., Mateus, C., Pautier, P., Saïag, P., Madonna, E., Maerevoet, M., Bout, J.-C., Leduc, C., Biscay, P., Quere, G., Nardin, C., Ebbo, M., Albigès, L., Marret, G., Levrat, V., Dujon, C., Vargaftig, J., Laghouati, S., Croisille, L., Voisin, A.-L., Godeau, B., Massard, C., Ribrag, V., Marabelle, A., Michel, M., & Lambotte, O.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2019-01
Volume
6
Issue
1
Pages
e48-e57
ISSN
2352-3026 (ISSN-L)
OpenAlex
W2902822641
Cited by
299
References
27
FWCI
9.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30175-3
The paper
Delanoy, N., Michot, J.-M., Comont, T., Kramkimel, N., Lazarovici, J., Dupont, R., Champiat, S., Chahine, C., Robert, C., Herbaux, C., Besse, B., Guillemin, A., Mateus, C., Pautier, P., Saïag, P., Madonna, E., Maerevoet, M., Bout, J.-C., Leduc, C., . . . Lambotte, O. (2019). Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30175-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.